JIJulio Iglesias

Julio Iglesias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julio Iglesias has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bone marrow characterization in COPD: a multi-level network analysis

    by Nuria Toledo-Pons, Guillaume Noell, Andreas Jahn, Amanda Iglesias, Maria Antonia Duran, Julio Iglesias, Angel Rios, Sergio Scrimini, Rosa Faner, Orlando Gigirey, et al.

    Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair. Yet, BM composition has not been previously characterized in COPD patients. In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8) and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network correlation analysis. We found that: (1) there were no major significant pair wise differences between COPD patients and controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies a relation between immunity, repair and lung function not previously described, that remains in the COPD network but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity and repair, particularly in patients with emphysema. Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients with more emphysema and/or higher circulating eosinophils.


  • Open Access

    Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases

    by Bernardo López-Andrade, Francesca Sartori, Antonio Gutiérrez, Lucia García, Vanesa Cunill, María Antonia Durán, Antonia Sampol, Marta Bernués, Julio Iglesias, Rafael Ramos, et al.


  • Open Access

    Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis

    by Jordi Martinez-Serra, Raquel Del Campo, Antonio Gutierrez, Jose Luis Antich, Magdalena Ginard, Maria A Durán, Leyre Bento, Teresa Ros, Juan C Amat, Carmen Vidal, et al.

    Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.